| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1070586 | Drug and Alcohol Dependence | 2009 | 6 Pages |
Abstract
No dosage modification of BUP/NLX is required when co-administered with TPV/r. Though mechanistically unclear, it is likely that decreased plasma RTV levels while on BUP/NLX contributed substantially to the decrease in TPV levels. BUP/NLX and TPV/r should therefore be used cautiously to avoid decreased efficacy of TPV in patients taking these agents concomitantly.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
R. Douglas Bruce, Frederick L. Altice, David E. Moody, Shen-Nan Lin, Wenfang B. Fang, John P. Sabo, Jan M. Wruck, Peter J. Piliero, Carolyn Conner, Laurie Andrews, Gerald H. Friedland,